Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UP-818-CC in Healthy Chinese Subjects
NCT07355621Phase 1Completed
- Sponsor
- EnliTISA
- Start
- Feb 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TISA-818 (4 arms), sponsored by EnliTISA. Primary endpoint: Treatment-Related Adverse Events at 10 days. Started Feb 2022; status: completed.
02
Drugs
TISA-818
Beyond the preview
Go deeper on NCT07355621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07355621.